An Oral SARS-CoV-2 M^pro Inhibitor Clinical Candidate for the Treatment of COVID-19

Investigators reported the discovery and characterization of PF-07321332, an orally bioavailable SARS-CoV-2 main protease inhibitor with in vitro pan-human coronavirus antiviral activity and excellent off-target selectivity and in vivo safety profiles.